Trial reportNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2011
Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis.
Trial report in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- Increased Risk of Myocardial Infarction in Inclusion Body Myositis: A Non-Concurrent Cohort Study.European journal of neurology · 2025Article
- Inclusion body myositis and immunosenescence: current evidence and future perspectives.Rheumatology (Oxford, England) · 2025Review
- Inclusion Body Myositis: Update on Pathogenesis and Treatment.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Review
- Classification and management of adult inflammatory myopathies.The Lancet. Neurology · 2018Review
- Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Inclusion body myositis - pathomechanism and lessons from genetics.Open medicine (Warsaw, Poland) · 2015Review
- Inclusion body myositis.Neurologic clinics · 2014Review
- Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group.The Journal of rheumatology · 2014Review
- Diagnosis, pathogenesis and treatment of myositis: recent advances.Clinical and experimental immunology · 2014Review
- Update on treatment of inclusion body myositis.Current rheumatology reports · 2013Review
- ANT1 is reduced in sporadic inclusion body myositis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013Article
- Inclusion body myositis.Current neurology and neuroscience reports · 2013Review
- Novel approaches in the treatment of myositis and myopathies.Therapeutic advances in musculoskeletal disease · 2012Article
- Inclusion body myositis.Seminars in neurology · 2012Review
- Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis.Muscle & nerve · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sporadic inclusion-body myositis (s-IBM) is a chronic progressive inflammatory myopathy leading to severe disability. It has been suggested that statins may benefit s-IBM patients based on their pleiotropic effects on autoimmunity and possible adverse influence of increased cholesterol on muscle pathological changes. We carried out a pilot, open-label trial to evaluate safety and tolerability of oral simvastatin in s-IBM patients. Fourteen patients were treated with 40 mg of simvastatin over 12 months. Primary outcome measures included the assessment tools proposed by International Myositis Outcome Assessment Collaborative Study group and the IBM-Functional Rating Scale. As additional data, we report the results obtained from muscle MRI, biopsy and oropharyngeal scintigraphy. Ten patients completed the trial and the treatment appeared safe and well tolerated. None of the patients showed a significant clinical improvement. Outcome measures used in this study proved to be valuable tools for global assessment of s-IBM patients. At present, we cannot recommend simvastatin as a treatment for s-IBM though our data may warrant a placebo-controlled study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.